Stock 4587 PEPTIDREAM INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PeptiDream Inc.

Equities

4587

JP3836750004

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
1,622 JPY +1.66% Intraday chart for PeptiDream Inc. +10.45% +9.12%
Mar. 13 Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI
Mar. 13 Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 269,659 192,662 210,224 - -
Enterprise Value (EV) 1 274,907 195,369 199,793 189,221 180,778
P/E ratio 35.7 x 63.5 x 29.9 x 23 x 20.9 x
Yield - - - 0.12% 0.37%
Capitalization / Revenue 10 x 6.71 x 6.11 x 5.42 x 5.05 x
EV / Revenue 10.2 x 6.8 x 5.81 x 4.88 x 4.35 x
EV / EBITDA 25.1 x 21.2 x 15.7 x 14 x 12.5 x
EV / FCF -72.3 x 17.4 x 22.4 x 14.8 x 11.5 x
FCF Yield -1.38% 5.74% 4.47% 6.77% 8.72%
Price to Book 8.42 x 4.78 x 4.78 x 3.88 x 3.18 x
Nbr of stocks (in thousands) 129,831 129,608 129,608 - -
Reference price 2 2,077 1,486 1,622 1,622 1,622
Announcement Date 2/14/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 26,852 28,712 34,394 38,780 41,599
EBITDA 1 10,954 9,206 12,754 13,481 14,495
EBIT 1 8,980 6,773 10,104 12,801 14,110
Operating Margin 33.44% 23.59% 29.38% 33.01% 33.92%
Earnings before Tax (EBT) 1 6,653 4,353 9,423 12,620 14,063
Net income 1 7,554 3,036 7,033 9,128 10,084
Net margin 28.13% 10.57% 20.45% 23.54% 24.24%
EPS 2 58.19 23.41 54.29 70.41 77.69
Free Cash Flow 1 -3,804 11,208 8,932 12,818 15,755
FCF margin -14.16% 39.04% 25.97% 33.05% 37.87%
FCF Conversion (EBITDA) - 121.74% 70.03% 95.08% 108.7%
FCF Conversion (Net income) - 369.19% 127% 140.43% 156.25%
Dividend per Share 2 - - - 2.000 6.000
Announcement Date 2/14/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 419 4,605 5,024 6,184 15,644 - 4,963 4,463 9,426 13,118 6,168 19,286 5,160 5,610 10,640 12,940 -
EBITDA - - - - - - - - - - - - - - - - -
EBIT 1 -1,166 -393 -1,559 1,133 9,407 - -266 -719.5 -986 7,739 20.2 7,759 -370 940 4,695 5,205 -
Operating Margin -278.28% -8.54% -31.03% 18.32% 60.13% - -5.36% -16.12% -10.46% 59% 0.33% 40.23% -7.17% 16.76% 44.13% 40.22% -
Earnings before Tax (EBT) -1,123 - -1,484 1,116 7,022 - -399 - -1,110 5,773 -308.5 5,464 - - - - -
Net income -829 - -1,056 870 7,741 - -248 - -729 4,270 -505.6 3,765 - - 2,650 4,460 -
Net margin -197.85% - -21.02% 14.07% 49.48% - -5% - -7.73% 32.55% -8.2% 19.52% - - 24.91% 34.47% -
EPS 2 -6.390 - -8.130 6.690 59.63 66.32 -1.920 -3.700 -5.620 32.92 -3.890 29.03 -2.550 4.710 25.49 28.07 -
Dividend per Share 2 - - - - - - - - - - - - - - - - -
Announcement Date 5/12/22 8/9/22 8/9/22 11/10/22 2/14/23 2/14/23 5/11/23 8/9/23 8/9/23 11/9/23 2/14/24 2/14/24 - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 5,248 2,707 - - -
Net Cash position 1 - - 10,431 21,002 29,446
Leverage (Debt/EBITDA) 0.4791 x 0.294 x - - -
Free Cash Flow 1 -3,804 11,208 8,932 12,818 15,755
ROE (net income / shareholders' equity) 26.3% 8.4% 16.7% 18.7% 17.4%
ROA (Net income/ Total Assets) 16.6% 6.53% 14.3% - -
Assets 1 45,450 46,493 49,180 - -
Book Value Per Share 2 247.0 311.0 340.0 418.0 510.0
Cash Flow per Share 2 73.40 42.20 70.10 129.0 171.0
Capex 1 3,721 1,213 1,285 1,527 1,527
Capex / Sales 13.86% 4.22% 3.74% 3.94% 3.67%
Announcement Date 2/14/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PeptiDream Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1,622 JPY
Average target price
2,667 JPY
Spread / Average Target
+64.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PEPTIDREAM INC. Stock PeptiDream Inc.
+9.12% 1.34B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4587 Stock
  4. Financials PeptiDream Inc.